A highly accomplished vision scientist and expert in retinal disease will be the keynote speaker at the 2023 George Kambara, MD Vision Science Symposium on Friday, April 14.
News
Residency Program to Expand
The Accreditation Council for Graduate Medical Education (ACGME) has approved the department’s request to accept an additional first-year resident, bringing the total from 3 to 4.
Global Cataract Symposium Draws Learners from Three Countries
57 participants from three countries attended the third session of the 2022-2023 Global Cataract Symposium on January 30, 2023. The quarterly virtual program is hosted on a rotating basis by the Department of Ophthalmology and Visual Sciences, University of Santo Tomas (UST) in the Philippines, and Dr. Shroff’s Charity Eye Hospital (SCEH) in India.
Meet Our New Residents
We are excited to welcome our new ophthalmology residents, who will be joining us July 1, 2023.
Remembering Dr. Alice McPherson
With great sadness, the University of Wisconsin-Madison Department of Ophthalmology and Visual Sciences mourns the passing of notable alumna, retina specialist, and vision research advocate Alice McPherson, MD on January 16th, 2023.
New Nanoparticles Deliver Therapy Brain-Wide, Edit Alzheimer’s Gene In Mice
Researchers at UW–Madison have engineered silicone nanoparticles to cross the blood-brain barrier in mice to deliver brain-wide gene editing therapy for Alzheimer’s disease.
UW Faculty Present at 2023 AUPO Annual Meeting
University of Wisconsin Department of Ophthalmology and Visual Sciences faculty members and staff will present at the 2023 Association of University Professors of Ophthalmology (AUPO) Annual Meeting in San Diego, CA January 24 – 28, …
Remembering Thomas Stevens, MD: 1938 – 2022
The Department of Ophthalmology and Visual Sciences is saddened by the loss of longtime professor and beloved department leader, Thomas Stevens, MD. Stevens died December 26, 2022, at the age of 84.
Clinical Trial Offers Hope to Patients with Dry Age-Related Macular Degeneration
A current clinical trial could lead to approval of a first-ever treatment option for patients with geographic atrophy (GA) secondary to age-related macular degeneration, a progressive, irreversible, and devastating eye disease.